Fig. 3: Risk of Adverse Events within 28 Days Following XBB.1.5-containing COVID-19 mRNA Vaccination by Vaccine Brand, Adjusted for COVID-19 Infection and Temporal Trends. | Nature Communications

Fig. 3: Risk of Adverse Events within 28 Days Following XBB.1.5-containing COVID-19 mRNA Vaccination by Vaccine Brand, Adjusted for COVID-19 Infection and Temporal Trends.

From: Evaluating the safety of XBB.1.5-containing COVID-19 mRNA vaccines using a self-controlled case series study

Fig. 3

Notes: Each outcome was studied separately. Encephalitis was omitted because it was not observed with significant cases in this study. Event counts fewer than 20 were replaced with ‘< 20’ in accordance with N3C regulation. IRR indicates incidence rate ratio, calculated using conditional Poisson regression. The primary analysis included patients who received either brand of the XBB.1.5-containing COVID-19 mRNA vaccines and experienced specific outcomes. This subgroup analysis was stratified by vaccine brands. The model was adjusted for COVID-19 infection and temporal trends. NE, not estimable.

Back to article page